Follow-up of patients with ECL cell-derived tumours

References

• Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol. 2003;12:153–172.
   PubMed Web of Science ®Google Scholar
• Qvigstad G, Falkmer S, Westre B, et al. Clinical and histopathological tumour progression in ECL cell carcinoids (“ECLomas”). Apmis. 1999;107:1085–1092.
   PubMed Web of Science ®Google Scholar
• Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104:994–1006.
   PubMed Web of Science ®Google Scholar
• Bordi C, D'Adda T, Azzoni C, et al. Pathogenesis of ECL cell tumors in humans. Yale J Biol Med. 1998;71:273–284.
   PubMed Web of Science ®Google Scholar
• Waldum HL, Brenna E, Sandvik AK. Relationship of ECL cells and gastric neoplasia. Yale J Biol Med. 1998;71:325–335.
   PubMed Web of Science ®Google Scholar
• Sjoblom SM, Sipponen P, Miettinen M, et al. Gastroscopic screening for gastric carcinoids and carcinoma in pernicious anemia. Endoscopy. 1988;20:52–56.
   PubMed Web of Science ®Google Scholar
• Ferrand A, Wang TC. Gastrin and cancer: a review. Cancer Lett. 2006;238:15–29.
   PubMed Web of Science ®Google Scholar
• Guillem P. [Gastric carcinoid tumours. Is there a place for antrectomy?]. Ann Chir. 2005;130:323–326.
   PubMedGoogle Scholar
• Fykse V, Sandvik AK, Waldum HL. One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release. Scand J Gastroenterol. 2005;40:1269–1274.
   PubMed Web of Science ®Google Scholar
• Grozinsky-Glasberg S, Kaltsas G, Gur C, et al. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol. 2008;159:475–482.
   PubMed Web of Science ®Google Scholar
• Grozinsky-Glasberg S, Grossman AB, Korbonits M. The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol. 2008;286:238–250.
   PubMed Web of Science ®Google Scholar
• Martinsen TC, Kawase S, Hakanson R, et al. Spontaneous ECL cell carcinomas in cotton rats: natural course and prevention by a gastrin receptor antagonist. Carcinogenesis. 2003;24:1887–1896.
   PubMed Web of Science ®Google Scholar
• Kidd M, Siddique ZL, Drozdov I, et al. The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development. Regul Pept. 2010;162:52–60.
   PubMedGoogle Scholar
• Moore AR, Boyce M, Steele IA, et al. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One. 2013;8:e76462.
   PubMed Web of Science ®Google Scholar
• Fossmark R, Sordal O, Jianu CS, et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther. 2012;36:1067–1075.
   PubMed Web of Science ®Google Scholar
• Crosby DA, Donohoe CL, Fitzgerald L, et al. Gastric neuroendocrine tumours. Dig Surg. 2012;29:331–348.
   PubMed Web of Science ®Google Scholar
• Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012;95:74–87.
   PubMed Web of Science ®Google Scholar
• Borch K, Ahren B, Ahlman H, et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005;242:64–73.
   PubMed Web of Science ®Google Scholar
• Grozinsky-Glasberg S, Thomas D, Strosberg JR, et al. Metastatic type 1 gastric carcinoid: a real threat or just a myth? World J Gastroenterol. 2013;19:8687–8695.
   PubMed Web of Science ®Google Scholar
• Spampatti MP, Massironi S, Rossi RE, et al. Unusually aggressive type 1 gastric carcinoid: a case report with a review of the literature. Eur J Gastroenterol Hepatol. 2012;24:589–593.
   PubMed Web of Science ®Google Scholar
• Kleveland PM, Haugen SE, Waldum HL. The preparation of bioactive 125I-gastrin, using Iodogen as oxidizing agent, and the use of this tracer in receptor studies. Scand J Gastroenterol. 1985;20:569–576.
   PubMed Web of Science ®Google Scholar
• Syversen U, Mignon M, Bonfils S, et al. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncol. 1993;32:161–165.
   PubMed Web of Science ®Google Scholar
• Syversen U, Jacobsen MB, O'Connor DT, et al. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides. 1994;26:201–206.
   PubMed Web of Science ®Google Scholar
• Johannessen R, Bergh K, Jianu C, et al. Polymerase chain reaction versus culture in the diagnosis of Helicobacter pylori infection. Gastroenterology Insights. 2013;5:1–6.
   Google Scholar
• Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut. 2007;56:631–636.
   PubMed Web of Science ®Google Scholar
• Solcia E, Fiocca R, Villani L, et al. Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis. Am J Surg Pathol. 1995;19(Suppl 1):S1–S7.
   PubMed Web of Science ®Google Scholar
• Thomas D, Tsolakis AV, Grozinsky-Glasberg S, et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol. 2013;168:185–193.
   PubMed Web of Science ®Google Scholar
• Lahner E, Galli G, Esposito G, et al. Updated features associated with type 1 gastric carcinoids patients: a single-center study. Scand J Gastroenterol. 2014;49:1447–1455.
   PubMed Web of Science ®Google Scholar
• Merola E, Sbrozzi-Vanni A, Panzuto F, et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology. 2012;95:207–213.
   PubMed Web of Science ®Google Scholar
• La Rosa S, Inzani F, Vanoli A, et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol. 2011;42:1373–1384.
   PubMed Web of Science ®Google Scholar
• Vannella L, Sbrozzi-Vanni A, Lahner E, et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther. 2011;33:1361–1369.
   PubMed Web of Science ®Google Scholar
• Borch K, Stridsberg M, Burman P, et al. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol. 1997;32:198–202.
   PubMed Web of Science ®Google Scholar
• Bakke I, Qvigstad G, Brenna E, et al. Gastrin has a specific proliferative effect on the rat enterochromaffin-like cell, but not on the parietal cell: a study by elutriation centrifugation. Acta Physiol Scand. 2000;169:29–37.
   PubMedGoogle Scholar
• Tielemans Y, Axelson J, Sundler F, et al. Serum gastrin concentration affects the self replication rate of the enterochromaffin like cells in the rat stomach. Gut. 1990;31:274–278.
   PubMed Web of Science ®Google Scholar
• Brenna E, Waldum HL. Trophic effect of gastrin on the enterochromaffin like cells of the rat stomach: establishment of a dose response relationship. Gut. 1992;33:1303–1306.
   PubMed Web of Science ®Google Scholar
• Bordi C, D'Adda T, Azzoni C, et al. Hypergastrinemia and gastric enterochromaffin-like cells. Am J Surg Pathol. 1995;19(Suppl 1):S8–S19.
   PubMed Web of Science ®Google Scholar
• Coupe M, Rees H, Springer CJ, et al. Gastric enterochromaffin-like (ECL) cells in hypergastrinaemic duodenal ulcer disease. Gut. 1990;31:144–147.
   PubMed Web of Science ®Google Scholar
• Sjoblom SM, Sipponen P, Karonen SL, et al. Mucosal argyrophil endocrine cells in pernicious anaemia and upper gastrointestinal carcinoid tumours. J Clin Pathol. 1989;42:371–377.
   PubMed Web of Science ®Google Scholar
• Bordi C. Gastric carcinoids. Ital J Gastroenterol Hepatol. 1999;31(Suppl 2):S94–S97.
   PubMed Web of Science ®Google Scholar
• Rindi G, Bordi C, Rappel S, et al. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996;20:168–172.
   PubMed Web of Science ®Google Scholar
• Wiedenmann B, Jensen RT, Mignon M, et al. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg. 1998;22:309–318.
   PubMed Web of Science ®Google Scholar
• Saund MS, Al Natour RH, Sharma AM, et al. Tumor size and depth predict rate of lymph node metastasis and utilization of lymph node sampling in surgically managed gastric carcinoids. Ann Surg Oncol. 2011;18:2826–2832.
   PubMed Web of Science ®Google Scholar
• Boutzios G, Griniatsos J, Dimitriou N, et al. The validity of current guidelines regarding surgical management of patients with gastric neuroendocrine neoplasms type 1: a report of a series of seven patients. Hormones (Athens). 2013;12:517–521.
   PubMedGoogle Scholar
• de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134:945–952.
   PubMed Web of Science ®Google Scholar
• Kokkola A, Sjoblom SM, Haapiainen R, et al. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol. 1998;33:88–92.
   PubMed Web of Science ®Google Scholar
• Waldum HL, Qvigstad G, Falkmer S. Indications for a neuroendocrine tumor-carcinoma sequence. Virchows Arch. 2001;439:215–217.
   PubMed Web of Science ®Google Scholar
• Chen WC, Warner RR, Ward SC, et al. Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience. Dig Dis Sci. 2015;60:996–1003.
   PubMed Web of Science ®Google Scholar
• Jianu CS, Fossmark R, Syversen U, et al. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scand J Gastroenterol. 2011;46:456–463.
   PubMed Web of Science ®Google Scholar
• Massironi S, Zilli A, Fanetti I, et al. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis. Dig Liver Dis. 2015;47:978–983.
   PubMedGoogle Scholar
• Hakanson R, Chen D, Tielemans Y, et al. ECL cells: biology and pathobiology. Digestion. 1994;55(Suppl 3):38–45.
   PubMed Web of Science ®Google Scholar